Compass Therapeutics (CMPX) Capital Expenditures (2019 - 2026)

Compass Therapeutics has disclosed Capital Expenditures across 8 years of filings, most recently posting $82000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $82000.0, up 355.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $89000.0 (up 43.55% YoY), and the FY2025 annual result was $25000.0, down 43.18% from the prior year.
• Capital Expenditures came in at $82000.0 for Q1 2026 at Compass Therapeutics, up from $7000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $194000.0 in Q1 2022 to a low of -$63000.0 in Q2 2022.
• The 5-year median for Capital Expenditures is $18000.0 (2025), against an average of $35727.3.
• Across the five-year window, Capital Expenditures tumbled 123.95% in 2022 and jumped 355.56% in 2026, its largest moves.
• Compass Therapeutics' Capital Expenditures stood at $54000.0 in 2022, then plunged by 83.33% to $9000.0 in 2023, then soared by 388.89% to $44000.0 in 2024, then tumbled by 84.09% to $7000.0 in 2025, then surged by 1071.43% to $82000.0 in 2026.
• The last three Capital Expenditures figures came in at $82000.0 (Q1 2026), $7000.0 (Q3 2025), and $18000.0 (Q1 2025), per Business Quant data.